Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed

I. D. Bernstein, J. W. Singer, R. G. Andrews, A. Keating, Jerry S Powell, B. H. Bjornson, J. Cuttner, V. Najfeld, G. Reaman, W. Raskind

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vivo cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly immature progenitors to be expressed.

Original languageEnglish (US)
Pages (from-to)1153-1159
Number of pages7
JournalJournal of Clinical Investigation
Volume79
Issue number4
StatePublished - 1987
Externally publishedYes

Fingerprint

Differentiation Antigens
Myeloid Cells
Acute Myeloid Leukemia
Stem Cells
Monoclonal Antibodies
Glucosephosphate Dehydrogenase
Granulocyte-Macrophage Progenitor Cells
Granulocytes
Therapeutics
Clone Cells
In Vitro Techniques
Monocytes
Leukemia
Bone Marrow

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. / Bernstein, I. D.; Singer, J. W.; Andrews, R. G.; Keating, A.; Powell, Jerry S; Bjornson, B. H.; Cuttner, J.; Najfeld, V.; Reaman, G.; Raskind, W.

In: Journal of Clinical Investigation, Vol. 79, No. 4, 1987, p. 1153-1159.

Research output: Contribution to journalArticle

Bernstein, ID, Singer, JW, Andrews, RG, Keating, A, Powell, JS, Bjornson, BH, Cuttner, J, Najfeld, V, Reaman, G & Raskind, W 1987, 'Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed', Journal of Clinical Investigation, vol. 79, no. 4, pp. 1153-1159.
Bernstein, I. D. ; Singer, J. W. ; Andrews, R. G. ; Keating, A. ; Powell, Jerry S ; Bjornson, B. H. ; Cuttner, J. ; Najfeld, V. ; Reaman, G. ; Raskind, W. / Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. In: Journal of Clinical Investigation. 1987 ; Vol. 79, No. 4. pp. 1153-1159.
@article{23c3d280131944cc95a97f136f5c72fc,
title = "Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed",
abstract = "Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vivo cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly immature progenitors to be expressed.",
author = "Bernstein, {I. D.} and Singer, {J. W.} and Andrews, {R. G.} and A. Keating and Powell, {Jerry S} and Bjornson, {B. H.} and J. Cuttner and V. Najfeld and G. Reaman and W. Raskind",
year = "1987",
language = "English (US)",
volume = "79",
pages = "1153--1159",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "4",

}

TY - JOUR

T1 - Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed

AU - Bernstein, I. D.

AU - Singer, J. W.

AU - Andrews, R. G.

AU - Keating, A.

AU - Powell, Jerry S

AU - Bjornson, B. H.

AU - Cuttner, J.

AU - Najfeld, V.

AU - Reaman, G.

AU - Raskind, W.

PY - 1987

Y1 - 1987

N2 - Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vivo cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly immature progenitors to be expressed.

AB - Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vivo cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly immature progenitors to be expressed.

UR - http://www.scopus.com/inward/record.url?scp=0023228244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023228244&partnerID=8YFLogxK

M3 - Article

C2 - 3470307

AN - SCOPUS:0023228244

VL - 79

SP - 1153

EP - 1159

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 4

ER -